- Adams, Katherine;
- Tastad, Katie J;
- Huang, Stacy;
- Ujamaa, Dawud;
- Kniss, Krista;
- Cummings, Charisse;
- Reingold, Arthur;
- Roland, Jeremy;
- Austin, Elizabeth;
- Kawasaki, Breanna;
- Meek, James;
- Yousey-Hindes, Kimberly;
- Anderson, Evan J;
- Openo, Kyle P;
- Reeg, Libby;
- Leegwater, Lauren;
- McMahon, Melissa;
- Bye, Erica;
- Poblete, Mayvilynne;
- Landis, Zachary;
- Spina, Nancy L;
- Engesser, Kerianne;
- Bennett, Nancy M;
- Gaitan, Maria A;
- Shiltz, Eli;
- Moran, Nancy;
- Sutton, Melissa;
- Abdullah, Nasreen;
- Schaffner, William;
- Talbot, H Keipp;
- Olsen, Kristen;
- Staten, Holly;
- Taylor, Christopher A;
- Havers, Fiona P;
- Reed, Carrie;
- Budd, Alicia;
- Garg, Shikha;
- O’Halloran, Alissa;
- Brammer, Lynnette
The 2022-23 influenza season shows an early rise in pediatric influenza-associated hospitalizations (1). SARS-CoV-2 viruses also continue to circulate (2). The current influenza season is the first with substantial co-circulation of influenza viruses and SARS-CoV-2 (3). Although both seasonal influenza viruses and SARS-CoV-2 can contribute to substantial pediatric morbidity (3-5), whether coinfection increases disease severity compared with that associated with infection with one virus alone is unknown. This report describes characteristics and prevalence of laboratory-confirmed influenza virus and SARS-CoV-2 coinfections among patients aged <18 years who had been hospitalized or died with influenza as reported to three CDC surveillance platforms during the 2021-22 influenza season. Data from two Respiratory Virus Hospitalizations Surveillance Network (RESP-NET) platforms (October 1, 2021-April 30, 2022),§ and notifiable pediatric deaths associated¶ with influenza virus and SARS-CoV-2 coinfection (October 3, 2021-October 1, 2022)** were analyzed. SARS-CoV-2 coinfections occurred in 6% (32 of 575) of pediatric influenza-associated hospitalizations and in 16% (seven of 44) of pediatric influenza-associated deaths. Compared with patients without coinfection, a higher proportion of those hospitalized with coinfection received invasive mechanical ventilation (4% versus 13%; p = 0.03) and bilevel positive airway pressure or continuous positive airway pressure (BiPAP/CPAP) (6% versus 16%; p = 0.05). Among seven coinfected patients who died, none had completed influenza vaccination, and only one received influenza antivirals.†† To help prevent severe outcomes, clinicians should follow recommended respiratory virus testing algorithms to guide treatment decisions and consider early antiviral treatment initiation for pediatric patients with suspected or confirmed influenza, including those with SARS-CoV-2 coinfection who are hospitalized or at increased risk for severe illness. The public and parents should adopt prevention strategies including considering wearing well-fitted, high-quality masks when respiratory virus circulation is high and staying up-to-date with recommended influenza and COVID-19 vaccinations for persons aged ≥6 months.